Table 4. Comparative table of SBRT outcomes for pulmonary oligometastases.
| Studies | Year of study | Study design | Patient cohort | PFS (months) | OS (months) | Fractionation regimen | LC rate | Toxicities | Key prognostic indicators |
|---|---|---|---|---|---|---|---|---|---|
| Sharma et al. (40) | 2019 | Retrospective | 206 patients | – | 33 | 51–60 Gy/3 f | 63% (2-year) |
– | Synchronous metastases, colorectal primary cancer |
| Niibe et al. (41) | 2015 | Retrospective | 34 patients | – | 20 | BED10 ≥75 Gy | 79.1% (2-year) |
No severe toxicities | – |
| Yamamoto et al. (42) | 2020 | Multicentre retrospective | 1,378 patients (1,547 lesions) | – | 60.3% (3-year) | BED10 ≥75 Gy | 86% (3-year) |
– | Maximum tumor diameter, dose calculation algorithm, overall treatment time, and colorectal primary origin |
| This study | 2022 | Retrospective | 101 patients (141 lesions) | 11 | 39 | 50–70 Gy/5–10 f | 89.4% (2-year) |
Grade 2 pneumonitis (10.9%) | Pre-treatment with immunotherapy |
SBRT, stereotactic body radiotherapy; PFS, progression-free survival; OS, overall survival; LC, local control; BED, biological equivalent dose; f, fractions.